{"prompt": "['Alliance A171601', '14.3 Pharmacokinetics: (Alliance A171601-PP1) Population Pharmacokinetics of Palbociclib', 'Alliance A171601- - PP1 will evaluate if palbociclib exposure (AUC/Cmux) is related to change', 'from baseline in neutrophil numbers i.e. neutropenia.', '14.3.1 Background and Hypotheses', 'Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).', 'The FDA approved regimen is a 125 mg capsule of palbociclib taken orally once daily for', '21 consecutive days followed by 7 days off treatment combined with letrozole 2.5 mg PO', 'daily, on 28-day cycles.', 'Palbociclib is slowly absorbed with a Tmax of 6-12h following an oral 125 mg dose, with a', 'mean Cmax of 133 (+/-SD 18.6) ng/mL. The terminal elimination half-life is mean 29 +/- 5', 'h, and steady state concentrations are usually reached in 8 days. The palbociclib is 85%', 'bound to plasma proteins and its geometric mean apparent volume of distribution (Vz/F)', 'was 2583 L with a coefficient of variation (CV) of 26%. The geometric mean apparent oral', 'clearance (CL/F) of palbocic lib was 63.1 L/hr (29%CV). In 6 healthy male subjects given', 'a single oral dose of 14C- palbociclib, a median of 91.6% of the total administered', 'radioactive dose was recovered in 15 days; feces (74.1% of dose) was the major route of', 'excretion, with 17.5% of the dose recovered in urine. The majority of the material was', 'excreted as metabolites.', 'Palbociclib absorption and exposure were very low in approximately 13% of the population', 'under the fasted condition. Food intake increased the palbociclib exposure in this small', 'subset of the population, but did not alter palbociclib exposure in the rest of the population', 'to a clinically relevant extent. Therefore, food intake reduced the intersubject variability of', 'palbociclib exposure, which supports administration of palboci lib with food. Compared to', 'palbociclib given under overnight fasted conditions, the population average area under the', 'concentration-time curve from zero to infinity (AUC(inf) and Cmax of palbocicl lib increased', 'by 21% and 38%, respectively, when given with high-fat, high-calorie food (approximately', '800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate, and', 'fat, respectively), by 12% and 27%, respectively, when given with low-fat, low-calorie food', '(approximately 400 to 500 calories with 120, 250, and 28 to 35 calories from protein,', 'carbohydrate, and fat, respectively), and by 13% and 24%, respectively, when moderate-fat,', 'standard calorie food (approximately 500 to 700 calories with 75 to 105, 250 to 350 and 175', 'to 245 calories from protein, carbohydrate, and fat, respectively) was given 1 hour before', 'and 2 hours after palbocic lib dosing.', 'In vitro and in vivo studies indicate that palbociclib undergoes hepatic metabolism in', 'humans. Following oral administration of a single 125 mg dose of 14C palbociclib to', 'humans, the primary metabolic pathways for palbociclib involved oxidation and', 'sulfonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib', 'was the major circulating drug-derived entity in plasma (23%). The major circulating', 'metabolite was a glucuronide conjugate of palbociclib although it only represented 1.5% of', 'the administered dose in the excreta. Palbociclib was extensively metabolized with', 'unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine,', 'respectively. In feces, the sulfamic acid conjugate of palbociclit was the major drug-related', 'component, accounting for 26% of the administered dose. Data from a clinical trial in', 'patients with breast cancer showed that there was no drug interaction between palbociclib', 'and letrozole when the 2 drugs were coadministered.', 'In vitro studies with human hepatocytes, liver cytosolic and S9 fractions, and recombinant', 'SULT enzymes indicated that CYP3A and SULT2A1 are mainly involved in the', '72', 'NCI Version Date: 5/29/2020', 'Update 5']['Alliance A171601', 'metabolism of palbociclib. In vivo, palbociclib exposure was increased by 1.9-fold when it', 'was coadministered with itraconazole (strong CYP3A4 inhibitor), and co-administration of', 'strong CYP3A4 inhibitors should be avoided. If co-administration with a strong CYP3A', 'inhibitor cannot be avoided, the daily palbociclib dose should be reduced to 75 mg. In vivo,', 'palbociclib exposure was decreased by 85% when it was coadministered with rifampin', '(strong CYP3A inducer), and co-administration of strong CYP3A inducers should be', 'avoided. The effect of moderate CYP3A inducers on palbociclib exposure is not known,', 'and co-administration of moderate CYP3A4 inducers should be avoided. Co-administration', 'of palbociclib with multiple doses of rabeprazole (proton pump inhibitor) under fed', 'conditions did not have a clinically significant effect on palbociclib exposure. In vitro,', 'palbociclib caused time-dependent inhibition of CYP3A4. Palbociclib increased the', 'midazolam (CYP3A substrate) AUC by 61% in healthy subjects, and therefore co-', 'administration of sensitive CYP3A substrates with narrow therapeutic indices should be', 'avoided.', 'Based on prior population pharmacokinetic analysis from male and female patients treated', 'with palbociclib, neither gender, age nor body weight had a clinically important effect on', 'palbociclib exposure. Furthermore, no dose reduction is needed in patients with mild or', 'moderate renal impairment, or mild hepatic impairment. No clinically significant change in', 'the QTc interval was detected when palboc ic lib was administered to steady state. Definitive', 'conclusions regarding an exposure-response relationship for progression free survival (PFS)', 'could not be made based on the limited data at a fixed dose of 125 mg from prior clinical', 'studies. However, a greater reduction in absolute neutrophil count is suggested to be', 'associated with increased palbociclib exposure. These exposure effect relationships for', 'older patients (over 70 and over 75 years of age) have not been defined.', 'The primary hypothesis of this population-pharmacokinet nested study is', '(1) That palbociclib exposure (AUC/Cmax) is related to change from baseline in neutrophil', 'numbers i.e. neutropenia.', 'Secondary exploratory hypotheses are that palbocic lib exposure is associated with (i) degree', 'of thrombocytopenia in older patients (ii) progression free survival in older patients (iii)', 'these relationships will be strengthened by consideration of known polymorphisms in', 'palbociclib drug metabolizing enzymes (especially CYP3A and SULT-2A1) and drug', 'transporters.', '14.3.2 Objectives:', 'To refine a population pharmacokinetic model (of Sun and Wang) using', 'NONMEM for palbociclib taking account of relevant intrinsic and extrinsic', 'factors.', 'To determine the intrapatient and interpatient variability of palbociclib (AUC) in', 'older breast cancer patients receiving palbociclib plus letrozole', 'To explore the exposure (AUC/Cmax) toxicity (neutropenia, thrombocytopenia)', 'relationship for palbociclib when combined with letrozole in older breast cancer', 'patients', '14.3.3 Methods', 'For patients in the study who are receiving palbociclib plus letrozole or fulvestrant, venous', 'blood samples for palbociclib concentrations will be obtained at baseline, and at the', 'scheduled follow-up clinic visits on day 15 of cycle 1 and cycle 2, while still receiving study', 'drug therapy. These samples will have the time of day they were obtained documented. At', '73', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}